FdaNdcDirectoryPulse / compare
BRYTLY vs HAIR REGROWTH TREATMENT: FdaNdcDirectoryPulse comparison
BRYTLY (2026-10-16) and HAIR REGROWTH TREATMENT (2026-10-22) are peer FdaNdcDirectoryPulse records.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Both records plus every comparable record, with all columns and source links · Card, Apple Pay, Google Pay or Link via Stripe
How does BRYTLY compare to HAIR REGROWTH TREATMENT?
| Field | BRYTLY | HAIR REGROWTH TREATMENT |
|---|---|---|
| Product | BRYTLY | HAIR REGROWTH TREATMENT |
| Generic name | Apraclonidine Hydrochloride | Minoxidil |
| NDC | 0065-8596 | 72288-681 |
| Labeler | Alcon Laboratories, Inc. | Amazon.com Services LLC |
| Product type | HUMAN OTC DRUG | HUMAN OTC DRUG |
| Approval pathway | NDA | ANDA |
| Application number | NDA220341 | ANDA075357 |
| Dosage form | SOLUTION/ DROPS | SOLUTION |
| Route | OPHTHALMIC | TOPICAL |
| Active ingredients | APRACLONIDINE HYDROCHLORIDE 1.25 mg/mL | MINOXIDIL 2 g/100mL |
| Marketing start | 2026-10-16 | 2026-10-22 |
| Package configurations | 3 | 1 |
| Launch Signal Score | 45/100 | 40/100 |
| Peer rank and all 500 records (CSV) | 🔒 Click to unlock → | |
| Official source URLs for every peer record | 🔒 Click to unlock → | |
Official records: BRYTLY · HAIR REGROWTH TREATMENT
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.